A Case of M-Paraprotein-Associated Polyneuropathy with Stable Response to Rituximab Therapy-Reference-Cited by-同舟云学术

A Case of M-Paraprotein-Associated Polyneuropathy with Stable Response to Rituximab Therapy

Published:2019 Issue:4 Volume:12 Page:74-77
ISSN:1997-6933
Container-title:Clinical oncohematology
language:
Short-container-title:Клиническая онкогематология

Author:

Potapenko Vsevolod Gennad'evich¹²^ORCID,Kiselev V.N.³^ORCID

Affiliation:

1. Municipal Clinical Hospital No. 31

2. IP Pavlov First Saint Petersburg State Medical University

3. AM Nikiforov Russian Center of Emergency and Radiation Medicine

Abstract

Monoclonal gammopathy of undetermined significance is diagnosed on the basis of an extensive search for a diagnostic reason as paraprotein secretion occurs in different diseases. One of such is demyelinating polyneuropathy associated with monodonal IgM and antibodies to myelin-assosiacted glycoprotein (AMDP). The first-line treatment of this disease is based on prednisolone, and intravenous immunoglobulin. The second-line therapy of treatment-resistant patients is not determined. The case report of patient with AMPD who received therapy with prednisone, azathio-prine, plasmapheresis is presented. Stable response was reached by rituximab.

Publisher

Practical Medicine Publishing House

Subject

Oncology,Hematology

Reference13 articles.

1. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl J. Med. 2002;346(8):564-9. doi: 10.1056/NEJMoa01133202.

2. Гинзберг М.А., Варламова Е.Ю., Рыжко В.В. и др. Клинико-нейрофизиологическое исследование хронической демиелинизирующей полиневропатии, ассоциированной с моноклональной секрецией. Медицинский совет. 2015;10:93-6.

3. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J. Peripher Nerv Syst. 2010;15(1):1-9. doi: 10.1111/j.1529-8027.2010.00245.x.

4. Dalakas MC, Rakocevic G., Salajegheh M. Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-93. doi: 10.1002/ana.21577.

5. Супонева Н.А., Павлов Э.В. Диагностика и базовая терапия хронических полиневропатий. Врач. 2009;4:43-4.